Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer.

Marco MoschiniVidit SharmaMatteo SoligoSarah PsutkaLaureano RangelStephen A BoorjianIgor FrankMatthew T GettmanR Houston ThompsonMatthew K TollefsonR Jeffrey Karnes

Published in: Scandinavian journal of urology (2019)

B.G.S. 9 and specifically pattern 5 + 4 P.Ca. is associated with substantial disease burden, adverse pathological features and the presence of locally advanced disease, in addition to inferior survival outcomes in comparison to b.G.S. 4 + 4 disease. Distinction of b.G.S. 9 patients from b.G.S. 8 patients at diagnosis may permit more precise pre-treatment risk stratification.

Keyphrases

prostate cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
radical prostatectomy
locally advanced
emergency department
radiation therapy
patient reported outcomes
neoadjuvant chemotherapy
patient reported
protein kinase
smoking cessation
electronic health record